Roche's new subcutaneous version measures up to IV Ocrevus in multiple sclerosis
Fierce Pharma
JULY 13, 2023
billion in 2020 to a projec | A phase 3 study has shown that a new, subcutaneous version of Roche's Ocrevus has proven to be non-inferior to the current infused treatment as measured by the level of drug in the blood, 12 weeks after administration.
233 
Let's personalize your content